Pharma Articles
Renowned pharmaceutical firm executives and other experts from around the world write articles on current topics in the industry. The section of articles on the pharmaceutical sector focuses on contemporary and expanding challenges in fields such as pharmaceutical R&D, drug discovery, clinical trials, pharmaceutical production, biopharmaceuticals, and information technology.
When Legacy Systems Hold Back Innovation
Every pharmaceutical company runs on systems it would never choose to build today Somewhere beneath the sleek dashboards and the ambitious digital roadmaps sits a substrate of older technology a manufacturing execution system commissioned two decades ago a quality database whose original architects...
The Translational Gap Is Killing Your Best Molecules
In todays rapidly evolving drug development landscape the translational gap has emerged as a critical challenge that is fundamentally reshaping how organizations approach research and development Its not just a scientific problem its a strategic imperative
Closing the Bench-to-Bedside Gap: Biomarker Strategies That Actually De-Risk Development
Biomarkers are measurable signals of what is happening in the body how a disease is progressing whether a drug is hitting its target or how a patient is responding They have moved from supporting roles to leading ones in modern drug development Yet many companies still use them reactively digging fo...
Autoantigen-Specific Biomarkers as Effector-Driven Therapeutic Targets
In the clinical laboratory the autoantibody has long occupied a modest role Detect antiMuSK antibodies and you have a diagnosis Detect antiaquaporin and you can predict a disease course Detect a particular antinuclear pattern and you can stratify a patients risk The antibody in this framing is a wit...
Analytical Strategies for Characterizing Complex Biologics and ADCs
This is not a laboratory footnote It is a capitalallocation reality The most sophisticated therapeutic modalities in modern medicine are also the most analytically demanding and the organizations that treat characterization as a strategic capabilityrather than a downstream compliance choreare the on...
Adaptive Trial Designs for Oncology: Efficiency Versus Regulatory Acceptance
For decades the randomized controlled trial has been the immovable gold standard of drug development fix the design lock the protocol enroll to a predetermined number and analyze only when the last patient crosses the finish line It is rigorous It is also in oncology frequently too slow too expensiv...
Generative AI in Drug Discovery: From Molecular Design to Translational Impact
Generative AI is changing how scientists think about drug discovery Rather than searching existing compound libraries or modifying known scaffolds these models can propose chemical ideas under defined constraints
Artificial Intelligence for the Digital Revolution of Pharmaceutical Manufacturing
Currently Artificial Intelligence AIMachine Learning ML model development programs are scattered and difficult to use particularly for scientists with less experience in computer programming eg Python Different computer programs are needed to deploy different AIML methods
Beyond Patent Expiry: The Next Decade of Biosimilars Will Be Won Through Commercial Excellence
The global biosimilar industry has reached an important inflexion point During the first wave of biosimilar development competitive advantage was largely defined by the ability to demonstrate analytical similarity obtain regulatory approval and offer meaningful cost savings compared with reference b...
How Account-Based Marketing (ABM) Drives Pharma Event Success and Lead Generation
For pharmaceutical companies conferences trade shows scientific congresses and industry networking events continue to be some of the most valuable channels for building relationships Yet many organizations still measure event success using outdated metrics such as booth visitors badge scans promotio...
